title: Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
abstract: OBJECTIVE
  To evaluate the 24-hour intraocular pressure (IOP)-lowering effect of latanoprost and the dorzolamide/timolol fixed combination (DTFC) after 2 and 6 months of treatment.
  
  
  METHODS
  Randomized, prospective, crossover comparison.
  
  
  METHODS
  Thirty-nine patients had primary open-angle glaucoma, and 14 patients had ocular hypertension.
  
  
  METHODS
  After a 6-week washout period, patients were randomized to either 6 months of treatment with the DTFC twice daily or latanoprost every evening and then crossed over to the opposite treatment for an additional 6 months.
  
  
  METHODS
  Mean 24-hour IOP after 2 and 6 months of treatment.
  
  
  RESULTS
  Fifty-three patients had an average 24-hour baseline IOP of 25.2+/-2.3 mmHg. After 6 months of treatment, 24-hour IOPs were 18.1+/-1.9 mmHg for the DTFC and 18.3+/-1.9 mmHg for latanoprost. Compared with 2 months of therapy, at 6 months the DTFC showed no significant change in mean 24-hour IOP, whereas latanoprost demonstrated a reduction of 0.3 mmHg (P = 0.01). The DTFC had more burning (P<0.001) and bitter taste (P = 0.01), whereas the latanoprost had more hypertrichosis (P = 0.02).
  
  
  CONCLUSIONS
  After 6 months of therapy, the DTFC and latanoprost have clinically similar 24-hour IOP-lowering efficacies.
authors.affiliation: Glaucoma Unit, First University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.
authors.forename: Anastasios G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: Vassilios P
authors.initials: VP
authors.lastname: Kozobolis
authors.forename: Sevasti
authors.initials: S
authors.lastname: Tsironi
authors.forename: Irene
authors.initials: I
authors.lastname: Makridaki
authors.forename: Rallitsa
authors.initials: R
authors.lastname: Efremova
authors.forename: William C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects*; D018592:Cross-Over Studies; D004338:Drug Combinations; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D011461:Prostaglandins F, Synthetic; D013449:Sulfonamides; D013876:Thiophenes; C479140:dorzolamide-timolol combination; D000077338:Latanoprost; D013999:Timolol